Although anti-rheumatoid arthritis (RA) 33 antibodies have been reported to be present in various connective tissue diseases (CTDs), the clinical significance of anti-RA33 in CTDs is still obscure. This study was performed to explore the clinical significance of anti-RA33 in CTDs, especially systemic lupus erythematosus (SLE). A total of 565 patients with positive anti-nuclear antibodies who had been tested for anti-RA33 were included in this study and were further classified into RA33-positive and RA33-negative groups. The association between anti-RA33 and the clinical features of CTDs was examined. Receiver operating characteristic (ROC) analysis was performed to explore the diagnostic value of anti-RA33 in SLE and SLE-related organ involvement. The results showed that SLE was the most common disease in CTD patients positive for anti-RA33 (48.8%). Compared with the RA33-negative group, higher proportions of SLE-associated antibodies and SLE patients with a high disease activity as well as lower levels of serum complement components were observed in the RA33-positive group (all p < 0.05). Furthermore, CTD patients with positive anti-RA33 were more likely to suffer from mucocutaneous and hematological involvement as well as interstitial lung disease (all p < 0.05). ROC analysis revealed an area under the curve value of 0.634 (95% confidence interval: 0.587–0.681) for anti-RA33 in the diagnosis of SLE, with a specificity and sensitivity of 92.9% and 13.5%, respectively. Taken together, this study reveals a significant association between anti-RA33 and the clinical features of CTDs, especially SLE, indicating a potential clinical significance of anti-RA33 in the management of SLE.
HassfeldWSteinerGHartmuthK, et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum1989; 32(12): 1515–1520.
2.
SteinerGHartmuthKSkrinerK, et al. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest1992; 90(3): 1061–1066.
3.
WangTHChenCCHsiaoYC, et al. Heterogeneous nuclear ribonucleoproteins A1 and A2 function in telomerase-dependent maintenance of telomeres. Cancers2019; 11(3): 334.
4.
CaporaliRBugattiSBruschiE, et al. Autoantibodies to heterogeneous nuclear ribonucleoproteins. Autoimmunity2005; 38(1): 25–32.
5.
Syed Mohamed SuhailSMNur AtiqahINur Salimi ZakirahZA, et al. Diagnostic performance of anti-RA33 antibody as a serological marker for rheumatoid arthritis. Malays J Pathol2019; 41(3): 259–265.
6.
NellVPMacholdKPStammTA, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis2005; 64(12): 1731–1736.
7.
SteinerGSmolenJ.Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res2002; 4(2 Supplement): S1–S5.
8.
HassfeldWSteinerGGraningerW, et al. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol1993; 32(3): 199–203.
9.
SkrinerKSommergruberWHTremmelV, et al. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue. J Clin Invest1997; 100(1): 127–135.
10.
SteinerGSkrinerKHassfeldW, et al. Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins—A link between RA, SLE and MCTD. Mol Biol Rep1996; 23(3): 167–71.
11.
HassfeldWSteinerGStudnicka-BenkeA, et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum1995; 38(6): 777–785.
12.
IsenbergDASteinerGSmolenJS.Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol1994; 21(7): 1260–1263.
13.
PetriMOrbaiAMAlarcónGS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686.
14.
HochbergM.Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40(9): 1725–1734.
15.
AringerMCostenbaderKDaikhD, et al. 2019 European league against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71(9): 1400–1412.
16.
VitaliCBombardieriSJonssonR, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis2002; 61(6): 554–558.
17.
ShiboskiSCShiboskiCHCriswellL, et al. American College of rheumatology classification criteria for Sjgren’s syndrome: a data-driven, expert consensus approach in the Sjgren’s International collaborative clinical alliance cohort. Arthritis Care Res (Hoboken)2012; 64(4): 475–487.
18.
ShiboskiCHShiboskiSCSerorR, et al. 2016 American college of Rheumatology/European league against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis2017; 76(1): 9–16.
19.
ArnettFCEdworthySMBlochDA, et al. The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31(3): 315–324.
20.
AletahaDNeogiTSilmanAJ, et al. 2010 Rheumatoid arthritis classification criteria: an American college of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum2010; 62(9): 2569–2581.
21.
BohanAPeterJB.Polymyositis and dermatomyositis. N Engl J Med1975; 292(8): 403–407.
22.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum1980; 23(5): 581–590.
23.
van den HoogenFKhannaDFransenJ, et al. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology/European league against Rheumatism collaborative initiative. Arthritis Rheum2013; 65(11): 2737–2747.
24.
MoscaMNeriRBombardieriS.Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol1999; 17(5): 615–620.
RudwaleitMLandewéRvan der HeijdeD, et al. The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis2009; 68(6): 770–776.
27.
RudwaleitMvan der HeijdeDLandewéR, et al. The development of assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis2009; 68(6): 777–783.
28.
RudwaleitMvan der HeijdeDLandewéR, et al. The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis2011; 70(1): 25–31.
29.
LindorKDBowlusCLBoyerJ, et al. Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases. Hepatology2019; 69(1): 394–419.
HoffmannMHTuncelJSkrinerK, et al. The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol2007; 179(11): 7568–7576.
38.
CordonnierCMeyerOPalazzoE, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol1996; 35(7): 620–624.
39.
BarbulescuALCiureaPLMitranC, et al. High frequency ultrasonography of the hand versus anti-RA33 evaluation in early rheumatoid arthritis – a pilot study. Med Ultrason2017; 19(2): 166–171.
40.
RiemekastenGMarellJTrebeljahrG, et al. A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest1998; 102(4): 754–763.
41.
GhirardelloADoriaAZampieriS, et al. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis2000; 59(12): 975–981.
42.
CairnsAPMcMillanSACrockardAD, et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis2003; 62(3): 272–273.
43.
EhrlichGE.Dubois’ Lupus Erythematosus. Williams & Wilkins.
44.
SchettGDumortierHHoeflerE, et al. B cell epitopes of the heterogeneous nuclear ribonucleoprotein A2: identification of a new specific antibody marker for active lupus disease. Ann Rheum Dis2009; 68(5): 729–735.
45.
Richter CohenMSteinerGSmolenJS, et al. Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol1998; 37(4): 421–424.
46.
BallEMTanALFukubaE, et al. A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status. Rheumatology (Oxford)2014; 53(10): 1835–1843.
47.
GuoTLongYShenQ, et al. Clinical profiles of SS-ILD compared with SS-NILD in a Chinese population: a retrospective analysis of 735 patients. Ann Med2021; 53(1): 1340–1348.
48.
ChenYWangYChenX, et al. Association of interstitial lung disease with clinical characteristics of Chinese patients with systemic lupus erythematosus. Arch Rheumatol2020; 35(2): 239–246.
49.
NarulaNNarulaTMira-AvendanoI, et al. Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. Clin Exp Rheumatol2018; 36(4): 648–651.
50.
SunKHTangSJWangYS, et al. Autoantibodies to dsDNA cross-react with the arginine-glycine-rich domain of heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) and promote methylation of hnRNP A2. Rheumatology (Oxford)2003; 42(1): 154–161.
51.
QuCZhangJZhangX, et al. Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus. Exp Ther Med2019; 17(2): 1390–1394.
52.
WangYLuoPGuoT, et al. Study on the correlation between anti-ribosomal P protein antibody and systemic lupus erythematosus. Medicine (Baltimore)2020; 99(20): e20192.
53.
FlechsigARoseTBarkhudarovaF, et al. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol2017; 35(4): 598–606.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
